CrystalGenomics Invites Co Ltd 083790
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- KRW 2,860.00
- Day Range
- KRW 2,350.00–2,760.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 2,605.00 / KRW 2,620.00
- Market Cap
- —
- Volume/Avg
- 1.2 Mil / 376,784
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 39.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 67
- Website
- http://www.crystalgenomics.com
Comparables
Valuation
|
Metric
|
083790
|
039200
|
271980
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 37.73 |
Price/Book Value | 1.46 | 13.40 | 1.58 |
Price/Sales | 39.46 | 253.37 | 0.34 |
Price/Cash Flow | — | — | 15.93 |
Price/Earnings
083790
039200
271980
Financial Strength
|
Metric
|
083790
|
039200
|
271980
|
|---|---|---|---|
Quick Ratio | 0.98 | — | 0.63 |
Current Ratio | 1.02 | 2.73 | 1.00 |
Interest Coverage | −24.58 | −90.11 | 1.15 |
Quick Ratio
083790
039200
271980
Profitability
|
Metric
|
083790
|
039200
|
271980
|
|---|---|---|---|
Return on Assets (Normalized) | −5.18% | −20.27% | 1.45% |
Return on Equity (Normalized) | −9.75% | −25.17% | 4.28% |
Return on Invested Capital (Normalized) | −7.09% | −26.91% | 4.70% |
Return on Assets
083790
039200
271980
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rfnwtkhmk | Tymqs | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bsqjgxtjb | Fntvh | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jzwnbwlw | Wvjph | $108.2 Bil | |
MRNA
| Moderna Inc | Qlcsbpdyy | Whvjc | $50.9 Bil | |
ARGX
| argenx SE ADR | Yrtfnzkl | Vmzqc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Fkxfmlmxs | Jwmc | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mqtgnqld | Vhkqnkd | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ggkgztk | Wypmtrz | $14.6 Bil | |
INCY
| Incyte Corp | Fgbgsnptg | Dpggktk | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wcjmtbscf | Xbtwxy | $12.3 Bil |